OLR1 and cancer: However, in this context, LOX-1 demonstrates the ability to bind Hsp70 and promote antigenic cross-presentation on DCs (29), thus making LOX-1 a potential target molecule for cancer therapies that rely on immunogenic cell death to spur anti-tumor responses.